BPC
ADVM

Banque Pictet & Cie’s Adverum Biotechnologies ADVM Stock Holding History

Banque Pictet & Cie’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-399
Closed -$216K – 466
2014
Q4 		$216K Buy
+399
New +$154K 0.01% 415

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Banque Pictet & Cie's ADVM Position: Q1 2015 in Review

Banque Pictet & Cie sold out of Adverum Biotechnologies (ADVM) in Q1 2015, closing a stake of 399 shares — an estimated $216K sold.

Banque Pictet & Cie first reported a position in ADVM in Q4 2014 and held it in 1 quarter. The position peaked at $216K in Q4 2014. 113 funds tracked by Wall St. Rank hold ADVM as of Q1 2015.

  • Banque Pictet & Cie reported no remaining Adverum Biotechnologies position as of Q1 2015 after selling out during the quarter.
  • Banque Pictet & Cie sold 399 Adverum Biotechnologies shares in Q1 2015, an estimated $216K.
  • Banque Pictet & Cie first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 1 quarter.
  • Banque Pictet & Cie's Adverum Biotechnologies position peaked at $216K in Q4 2014.
  • 113 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2015.

Based on Banque Pictet & Cie's 13F filing for Q1 2015, filed 8 May 2015.